REGN

Regeneron Pharmaceuticals Inc

REGN, USA

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

https://www.regeneron.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
REGN
stock
REGN

40 teen scientists vie for $1.8M at Regeneron talent search Stock Titan

Read more →
REGN
stock
REGN

YieldBoost REGN From 0.5% To 5.6% Using Options Nasdaq

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$797.2692

Analyst Picks

Strong Buy

14

Buy

5

Hold

5

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

High

18.28

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

2.63

Low 1

High 3

Return on Equity (ROE)

-

Very Low

4.72 %

Low 5%

High 25%

Return on Assets (ROA)

-

Low

3.63 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

37.75 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.30

Low 1

High 0.3

Investors

* Institutions hold a combined 77.59% of the total shares of Regeneron Pharmaceuticals Inc

1.

Vanguard Group Inc

(8.8917%)

since

2025/06/30

2.

BlackRock Inc

(8.7521%)

since

2025/06/30

3.

State Street Corp

(4.559%)

since

2025/06/30

4.

JPMorgan Chase & Co

(3.7171%)

since

2025/06/30

5.

Dodge & Cox

(3.6101%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(3.1491%)

since

2025/07/31

7.

FMR Inc

(3.1391%)

since

2025/06/30

8.

Capital Research & Mgmt Co - Division 3

(2.9865%)

since

2025/06/30

9.

Vanguard 500 Index Investor

(2.4252%)

since

2025/07/31

10.

Dodge & Cox Stock I

(2.3507%)

since

2025/06/30

11.

Geode Capital Management, LLC

(2.3258%)

since

2025/06/30

12.

Franklin Resources Inc

(2.1828%)

since

2025/06/30

13.

Invesco QQQ Trust

(2.0643%)

since

2025/08/29

14.

Capital World Investors

(1.855%)

since

2025/06/30

15.

Loomis, Sayles & Company LP

(1.8314%)

since

2025/06/30

16.

Fidelity 500 Index

(1.242%)

since

2025/07/31

17.

Morgan Stanley - Brokerage Accounts

(1.2149%)

since

2025/06/30

18.

Fidelity Contrafund

(1.2071%)

since

2025/07/31

19.

SPDR® S&P 500® ETF

(1.1813%)

since

2025/08/31

20.

iShares Core S&P 500 ETF

(1.1787%)

since

2025/08/31

21.

Bank of America Corp

(1.1514%)

since

2025/06/30

22.

NORGES BANK

(1.1289%)

since

2025/06/30

23.

American Funds New Perspective A

(1.1117%)

since

2025/06/30

24.

Capital Group New Perspective Comp

(1.1117%)

since

2025/06/30

25.

Amvescap Plc.

(1.015%)

since

2025/06/30

26.

Putnam Large Cap Value A

(1.0035%)

since

2025/07/31

27.

Putnam US Large Cap Value Equity

(1.0035%)

since

2025/06/30

28.

American Funds Growth Fund of Amer A

(0.9304%)

since

2025/06/30

29.

Capital Group Growth Fnd of Amer Comp

(0.9304%)

since

2025/06/30

30.

Northern Trust Corp

(0.9044%)

since

2025/06/30

31.

Vanguard Value Index Inv

(0.8876%)

since

2025/07/31

32.

Two Sigma Advisers, LLC

(0.8855%)

since

2025/06/30

33.

Amundi

(0.8465%)

since

2025/06/30

34.

UBS Asset Mgmt Americas Inc

(0.8118%)

since

2025/06/30

35.

Nuveen, LLC

(0.794%)

since

2025/06/30

36.

Capital Group American Mutual Comp

(0.6799%)

since

2025/06/30

37.

American Funds American Mutual A

(0.6799%)

since

2025/06/30

38.

The Health Care Select Sector SPDR® ETF

(0.6691%)

since

2025/08/31

39.

Vanguard Institutional Index I

(0.5923%)

since

2025/07/31

40.

iShares Biotechnology ETF

(0.5856%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

10.77

Latest Release

Date

2025-09-30

EPS Actual

11.83

EPS Estimate

9.67

EPS Difference

2.16

Surprise Percent

22.3371%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7.5)
Dividend
Decent Dividend Payer(5)
Economic Moat
Wide Moat Company(9.3)
GARP
Fair GARP(5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(4)
Quality
High Quality(8.5)
Value
Undervalued(8)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.